This document summarizes the drug levosimendan, which was developed as a new inotropic agent to increase contractility without the side effects of existing drugs like dobutamine. It has a triple mechanism of action: binding to cardiac troponin C to increase contractility, opening potassium channels in blood vessels to cause vasodilation, and opening mitochondrial potassium channels in cardiomyocytes for cardioprotection. Levosimendan does not increase intracellular calcium levels or oxygen consumption. It provides benefits like preconditioning and reduces remodeling, apoptosis, and inflammation in heart failure. Levosimendan was found to improve outcomes compared to dobutamine and other existing inotropic drugs.